SEC Filing Analysis: Zivo Bioscience, Inc. (ZIVO)

Executive Summary

• Trading Significance: High
• Key Takeaway: A dual-role insider (Director and 10% Owner) executed a substantial open-market purchase of common stock, signaling strong bullish sentiment and conviction.
• Market Impact: This transaction is likely to be viewed positively by the market, as open-market purchases by highly informed insiders are often interpreted as a belief that the stock is undervalued.

Company Information

Field	Value
Company	Zivo Bioscience, Inc.
Ticker Symbol	ZIVO
CIK	0001101026
Industry	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]

Insider Information

Field	Value
Name	Maggiore Christopher D.
CIK	0001436075
Title/Position	null
Relationship	Director, 10% Owner

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-10-08
Transaction Code	P (Open Market Purchase)
Security Type	Common Stock
Shares Involved	23,682
Price Per Share	$12.01
Total Value	$284,420.82
Shares Owned After	517,526
Ownership Type	Direct

Market Impact Analysis

Stock Impact Prediction

• Direction: Positive
• Reasoning: Open-market purchases by insiders with significant roles (Director and 10% Owner) are one of the strongest bullish signals. This action demonstrates a direct financial commitment and belief in the company's future performance, using personal funds.

Volume & Sentiment

• Expected Volume Impact: A potential short-term increase in trading volume as the market digests this information.
• Sentiment Indicator: Bullish. The trade aligns the insider's financial interests directly with those of shareholders.

Investment Insights

Positive Market Indicators

• High-Conviction Buy: The transaction value of over $284,000 is substantial.
• Dual-Role Insider: The purchase was made by an individual who is both a Director and a major shareholder, providing them with deep insight into the company's operations and strategic direction.
• Direct Ownership: The shares were acquired directly, indicating a personal investment rather than through a trust or other entity.

Risk Factors

• While a strong signal, this single transaction should be considered alongside broader company performance, financials, and market conditions.

Key Takeaways

1. Strong Insider Confidence: A key insider is increasing their stake in the company through an open-market purchase.
2. Significant Investment: The size of the purchase is meaningful, suggesting more than a token acquisition.
3. Ownership Correction: The filing clarifies the insider's total holdings, correcting a previous overstatement and confirming a substantial post-transaction ownership of 517,526 shares.

Contextual Analysis

Timing Significance

This purchase occurs without any specified 10b5-1 trading plan, suggesting it was a discretionary decision made based on current information and market conditions. Analyzing this against recent stock performance and company news could provide further insight.

Transaction Context

Footnote 1 reveals that a previous filing had overstated the insider's holdings by 13,156 shares due to an administrative error. This Form 4 serves to both report the new purchase and correct the public record of the insider's total beneficial ownership.

Company Context

Zivo Bioscience operates in the biological products sector. Investors should consider this trade in the context of the company's recent clinical trial results, product development pipeline, and overall financial health.

Risk Assessment

Risk Level: Low

Risk Factors

• The analysis is based on a single event; it does not guarantee future stock performance.
• The biotech sector can be volatile, subject to regulatory hurdles and clinical trial outcomes.

Market Considerations

• The market may have already priced in some expectations, potentially muting the impact.
• Broader market sentiment and economic conditions will also influence the stock's direction.

---

IMPORTANT DISCLAIMER: This analysis is for informational purposes only and is not intended as investment advice. The information presented is based on publicly available SEC filings and should not be construed as a recommendation to buy, sell, or hold any securities. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Please consult with a qualified financial advisor before making any investment decisions.

Analysis generated on 2025-10-09 | Data source: SEC EDGAR